User login
Key clinical point: The addition of atezolizumab to the first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) + bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC) without compromising safety.
Major finding: At a median follow-up of 19.9 months, patients receiving FOLFOXIRI + bevacizumab and atezolizumab vs. FOLFOXIRI + bevacizumab had a significantly longer median PFS (13.1 vs. 11.5 months; adjusted hazard ratio 0.70; P = .018), with serious adverse events being reported in 27% vs. 26% of patients, respectively.
Study details: The data come from a phase 2 study, AtezoTRIBE, that included 218 adult patients with previously untreated mCRC who were randomly assigned to receive FOLFOXIRI + bevacizumab (n = 73) or FOLFOXIRI + bevacizumab and atezolizumab (n = 145).
Disclosures: The study was sponsored by the GONO and ARCO Foundations, F Hoffmann-La Roche, and Roche. Some authors declared serving as consultants/advisors for or receiving honoraria or speaker/consulting fees from various sources, including Roche.
Source: Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022 (May 27). Doi: 10.1016/S1470-2045(22)00274-1
Key clinical point: The addition of atezolizumab to the first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) + bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC) without compromising safety.
Major finding: At a median follow-up of 19.9 months, patients receiving FOLFOXIRI + bevacizumab and atezolizumab vs. FOLFOXIRI + bevacizumab had a significantly longer median PFS (13.1 vs. 11.5 months; adjusted hazard ratio 0.70; P = .018), with serious adverse events being reported in 27% vs. 26% of patients, respectively.
Study details: The data come from a phase 2 study, AtezoTRIBE, that included 218 adult patients with previously untreated mCRC who were randomly assigned to receive FOLFOXIRI + bevacizumab (n = 73) or FOLFOXIRI + bevacizumab and atezolizumab (n = 145).
Disclosures: The study was sponsored by the GONO and ARCO Foundations, F Hoffmann-La Roche, and Roche. Some authors declared serving as consultants/advisors for or receiving honoraria or speaker/consulting fees from various sources, including Roche.
Source: Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022 (May 27). Doi: 10.1016/S1470-2045(22)00274-1
Key clinical point: The addition of atezolizumab to the first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) + bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC) without compromising safety.
Major finding: At a median follow-up of 19.9 months, patients receiving FOLFOXIRI + bevacizumab and atezolizumab vs. FOLFOXIRI + bevacizumab had a significantly longer median PFS (13.1 vs. 11.5 months; adjusted hazard ratio 0.70; P = .018), with serious adverse events being reported in 27% vs. 26% of patients, respectively.
Study details: The data come from a phase 2 study, AtezoTRIBE, that included 218 adult patients with previously untreated mCRC who were randomly assigned to receive FOLFOXIRI + bevacizumab (n = 73) or FOLFOXIRI + bevacizumab and atezolizumab (n = 145).
Disclosures: The study was sponsored by the GONO and ARCO Foundations, F Hoffmann-La Roche, and Roche. Some authors declared serving as consultants/advisors for or receiving honoraria or speaker/consulting fees from various sources, including Roche.
Source: Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022 (May 27). Doi: 10.1016/S1470-2045(22)00274-1